Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P28039

UPID:
AOAH_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P28039; A4D1Y5; B7Z490; Q53F13

BACKGROUND:
The enzyme Acyloxyacyl hydrolase is instrumental in the body's defense mechanism against Gram-negative bacterial infections. It functions by cleaving acyloxyacyl-linked fatty acyl chains from lipid A in lipopolysaccharides, effectively neutralizing the endotoxic effects of bacterial lipopolysaccharides. This process is vital for the resolution of inflammatory responses and recovery from immune tolerance induced by bacterial infections.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Acyloxyacyl hydrolase offers a promising avenue for the development of novel therapeutic interventions. Its critical role in managing the immune response to bacterial infections positions it as a potential target for creating innovative treatments to mitigate harmful inflammation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.